Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients
Huzarski, T, Byrski, T, Gronwald, J, et al., "The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients," Breast Cancer Research and Treatment, Vol. 156, No. 2, pp. 371-378, April 2016. (Subscription may be required for access to full text.)
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2, "No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer," Gynecologic Oncology, Vol. 141, No. 2, pp. 386-401, May 2016. (Subscription may be needed for full text.)
Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families
Noah D. Kauff, Nandita Mitra, Mark E. Robson, Karen E. Hurley, Shaokun Chuai, Deborah Goldfrank, Eve Wadsworth, Johanna Lee, Tessa Cigler, Patrick I. Borgen, Larry Norton, Richard R. Barakat, Kenneth Offit. Journal of the National Cancer Institute. Volume 97, issue 18: p. 1382-1384, September 2005.
Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis
Cybulski, C, Kluźniak, W, Huzarsk,i T, et al., "Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis," Lancet Oncology, Vol. 16, No. 6, pp. 638-644, June 2015.
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment
Mark E. Robson, Pierre O. Chappuis, Jaya Satagopan, Nora Wong, Jeff Boyd, John R. Goffin, Clifford Hudis, David Roberge, Larry Norton, Louis R. Bégin, Kenneth Offit, and William D. Foulkes. Breast Cancer Research. Volume 6, Number 1: R8-R17, October 2003.
Expand+BRCA1 Functions as a Differential Modulator of Chemotherapy-induced Apoptosis
Jennifer E. Quinn, Richard D. Kennedy, Paul B. Mullan, Paula M. Gilmore, Michael Carty, Patrick G. Johnston and D. Paul Harkin. Cancer Research. Volume 63: p. 6221-6228, October 2003.
Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma
John R. Goffin, M.D., Pierre O. Chappuis, M.D., Louis R. Bégin, M.D., Nora Wong, M.Sc., Jean-Sébastien Brunet, M.Sc., Nancy Hamel, M.Sc., Ann-Josée Paradis, B.Sc., Jeff Boyd, Ph.D., William D. Foulkes, M.B., Ph.D.. Cancer. Volume 97, Issue 3: p. 527-536, January 2003
Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy
Pål Møller, Åke Borg, D. Gareth Evans, Neva Haites, Marta M. Reis, Hans Vasen, Elaine Anderson, C. Michael Steel, Jaran Apold, David Goudie, Anthony Howell, Fiona Lalloo, Lovise Mæhle, Helen Gregory, Ketil Heimdal. International Journal of Cancer. Volume 101, Issue 6: p. 555-559, August 2002.
Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors
Y. Ben David, A. Chetrit, G. Hirsh-Yechezkel, E. Friedman, B.D. Beck, U. Beller, G. Ben-Baruch, A. Fishman, H. Levavi, F. Lubin, J. Menczer, B. Piura, J.P. Struewing, B. Modan. Journal of Clinical Oncology. Volume 20, Issue 2: p. 463-466, January 2002.
Effect of Radiotherapy After Breast-Conserving Treatment in Women With Breast Cancer and Germline BRCA1/2 Mutations
Lori J. Pierce, Myla Strawderman, Steven A. Narod, Ivo Oliviotto, Andrea Eisen, Laura Dawson, David Gaffney, Lawrence J. Solin, Asa Nixon, Judy Garber, Christine Berg, Claudine Isaacs, Ruth Heimann, Olufunmilayo I. Olopade, Bruce Haffty, Barbara L. Weber. Journal of Clinical Oncology. Volume 18, Issue 19: p. 3360-3369, October 2000.